Vical Incorporated – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
SummaryPharmaceuticals and Healthcare
Key Findings
Pharmaceuticals and Healthcare
Pharmaceuticals and Healthcare
Reasons To Buys
MarketLine
Key Highlights
United States
Vical researches and develops biopharmaceutical products, including those based on the company's patented DNA delivery technologies, for the prevention and treatment of serious or life-threatening diseases. The company has three active development programs in the area of infectious disease comprised of: HSV-2 therapeutic vaccine, VCL-HB01, to treat patients with symptomatic genital herpes infection; antifungal VL-2397 for the treatment of patients with invasive aspergillosis; and an ongoing early stage development program of a treatment for chronic hepatitis B virus infection based on its DNA and lipid-delivery technologies.
MarketLine, a world-leading provider of commercial intelligence, has over 400 experienced analysts, consultants, and researchers with regional and sector expertise in market sizing, competitor tracking, socio and macro economics, and business drivers.
For more than 15 years MarketLine has supported the research needs of investment banks, corporations, professional services firms, and academia with a unique mix of company, industry, country, city and financial data for every major industry and marketplace.
MarketLine’ holistic business intelligence report collection includes:
Industry Intelligence
‒ Industry Profiles
‒ Market Forecasts
‒ Porter’s Five Forces Analysis
Company Intelligence
‒ Company Profiles
‒ SWOT Analysis
‒ Financial Deals
Country and City Intelligence
‒ Country and City Profiles
‒ PEST/PESTLE Analysis
‒ Socio and macro-economic indicators
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.